Sesen Bio Inc Regulatory Update June 2019
שיחת ועידה Sesen Bio Inc
Sesen Bio Inc Conference call or earnings call will be held on 10/06/2019 via an 800 number (toll-free). During the earnings conference call's session Sesen Bio Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Sesen Bio Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are a preclinical stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that we apply to the discovery and development of protein therapeutics to treat diseases of the eye. Our therapeutic approach is based on the role of cytokines in diseases of the eye, our understanding of the structural biology of cytokines and our ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects. Our most advanced product candidate, which is still in preclinical development, is EBI-031, which we designed, engineered and generated using our AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema, or DME, and uveitis.קרא עוד שיחת ועידה